OneChain Immunotherapeutics is advancing the future of CAR-T with a differentiated in vivo platform designed for scalable, accessible cancer immunotherapy
OneChain Immunotherapeutics is advancing the future of CAR-T with a differentiated in vivo platform designed for scalable, accessible cancer immunotherapy. The company is focused on developing CAR-T therapies for oncological diseases, particularly targeting aggressive subtypes of T-cell leukemia.